OptiNose, Inc.
optinose.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 14, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells XHANCE, a nasal spray for chronic sinusitis with or without nasal polyps, to patients treated by ear, nose and throat and allergy specialists.
10-K for FY2024, filed Mar 26, 2025We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose…View ↗
How Did They Make Money?
Sells XHANCE to preferred pharmacy partners and wholesalers, whose onward sales reach pharmacies, hospitals, healthcare providers and patients. Product sales count when customers receive delivery; customer payment terms are no longer than one year.
10-K for FY2024, filed Mar 26, 2025
$78.2M
-
10-K for FY2024, filed Mar 26, 2025
$78.2M ↗
Who Were Their Customers?
Sells XHANCE to preferred pharmacy network partners and wholesale pharmaceutical distributors, who then resell it to pharmacies, hospitals, healthcare providers and patients.
10-K for FY2024, filed Mar 26, 2025
Did Revenues Turn Into Profits?
No. It lost $21.5M in FY2024.
10-K for FY2024, filed Mar 26, 2025
−$16.3MView ↗
10-K for FY2024, filed Mar 26, 2025
−$21.5MView ↗
10-K for FY2024, filed Mar 26, 2025
−$44.8MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 15, 2025
−$22.4MView ↗
- ▲ +59% (Loss)
- vs −$14.1M in Q1 FY2024
-
May 21, 2025
Paratek completed its acquisition of OptiNose
OptiNose became a wholly owned subsidiary; shareholders received $9 per share in cash plus contingent value rights.
Sources
8-K, filed May 21, 2025
Upon the closing of the Merger (the “Closing”), each outstanding share of the Company’s common stock, par value $0.001 per share (“Company…View ↗
Grew. Revenue grew 59% in 4 years, from $49.1M in FY2020 to $78.2M in FY2024, about 12% a year.
Expanded approved use
The older report describes XHANCE as approved for nasal polyps, with use for chronic sinusitis without polyps still conditional on approval; the latest describes it as approved for both conditions.
10-K for FY2021, filed Mar 8, 2022 10-K for FY2024, filed Mar 26, 2025We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose…View ↗
In March 2024, the FDA approved XHANCE for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and…View ↗
Who Did They Compete With?
Competes with Merck &, GlaxoSmithKline, Lyra Therapeutics, and Insmed
10-K for FY2024, filed Mar 26, 2025The only other branded INS to receive an indication for the treatment of nasal polyps is Nasonex™, which was marketed by Merck & Co., Inc.…View ↗
Loading...
